OcuTerra

Creating a clear vision for the treatment of ophthalmic diseases

Observations From Phase 2 of the DR:EAM Study

Carl D. Regillo, MD, FACS

Carl D. Regillo, MD, FACS, discusses some observations from phase 2 of the DR:EAM study to evaluate the efficacy and safety of OTT166 ophthalmic solution (Ocuterra) to treat diabetic retinopathy. He comments on data from the phase 1 trial and explains how patients have responded during enrollment in phase 2.

Videos From Ocuterra

Fact or Fiction: Can a Topical Formulation Reach the Retina?

Carl D. Regillo, MD, FACS, David A. Eichenbaum, MD, and Anat Loewenstein, MD, MHA

Fact or Fiction: Are Integrin Inhibitors a Viable Strategy?

Carl D. Regillo, MD, FACS, David A. Eichenbaum, MD, and Anat Loewenstein, MD, MHA

Fact or Fiction: Will Compliance Be an Issue With a Topical Drop for DR?

Carl D. Regillo, MD, FACS, David A. Eichenbaum, MD, and Anat Loewenstein, MD, MHA

Observations From Phase 2 of the DR:EAM Study

Carl D. Regillo, MD, FACS

OTT166 For Diabetic Retinopathy

Resources

Current Practice and Future Options for Nonproliferative Diabetic Retinopathy

View Resource

DR Research Roundup: Phase 2 and 3

View Resource

Shifting the Paradigm

View Resource

Current Practice and Future Options for Nonproliferative Diabetic Retinopathy

View Resource

Learn More

Interested in Learning More about the DREAM Study?

To find out more about the phase 2 DREAM study of OTT166 in eyes with diabetic retinopathy and how you can refer your patients, please contact the representative from Parexel, the CRO assisting OcuTerra in facilitating the DREAM study, listed below.

Learn More

About Ocuterra

OcuTerra is led by a team with significant biotechnology entrepreneurial and ophthalmology drug development experience and supported by the field’s leading scientific and clinical advisors.

Visit us online: ocuterratx.com

Follow Ocuterra